TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Posterior cortical atrophy (PCA) affects the brain’s processing of visual and spatial information, so early symptoms can include trouble reading, judging distances and navigating rather than obvious memory loss. Being Patient reports that diagnosis may take time, and that current treatments and support tailored to PCA remain limited.
A Being Patient report describes how posterior cortical atrophy (PCA), a syndrome that disrupts the brain’s processing of visual and spatial information, can first appear as difficulty seeing and carrying out everyday tasks—not as a familiar memory problem. The account follows Andrew Reid, who was diagnosed at age 56 after symptoms persisted despite earlier medical care, and highlights the challenges of recognizing the condition and finding support suited to it.
Reid first struggled to see his keyboard at work and write simple emails, according to Being Patient. He later had a close call while driving with his family after he zoned out at an intersection. An emergency department doctor initially diagnosed epilepsy, the report says. After about a year of treatment without the symptoms resolving, Reid and his wife, Karina, reached a brain clinic and received a PCA diagnosis.
PCA affects the brain regions involved in interpreting visual information and orienting in space; the visual difficulties are not necessarily caused by an eye problem. Reported symptoms include trouble reading, sensitivity to bright light, misplacing objects, judging distances, recognizing faces or objects, and navigating. As the syndrome progresses, tasks such as dressing, eating or positioning oneself on a chair may become harder. The report says memory, speech, language and executive function can also be affected later.
About 80 percent of PCA cases are attributed to Alzheimer’s disease, according to the report. Other stated causes include dementia with Lewy bodies, prion disease and other neurodegenerative conditions. There is no cure for PCA. Some people may receive medications used for Alzheimer’s or, depending on the underlying cause, other conditions, but the report says evidence about their effectiveness specifically for PCA is limited.
When Visual Symptoms Disrupt Daily Life
PCA can affect independence in ways that differ from the memory difficulties commonly associated with dementia. A person may retain insight or memory while having increasing difficulty moving safely through familiar spaces, dressing, eating or driving. That mismatch can make the condition hard for families and services to recognize, and can leave people with needs that standard dementia support may not address well.
Diagnosis matters because visual-processing problems can have causes other than PCA, and assessment can help clarify what is happening. The report describes recommended steps including a detailed eye examination to rule out eye disease, blood tests for other conditions, cognitive testing and brain imaging. Identifying the underlying disease may also inform discussions about treatment, though the source stresses that evidence for PCA-specific benefits is limited.
Products Worth Considering
Levoit Core 400S-P Smart Air Purifier for Large Rooms
Bowflex PR1000 Home Gym
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black, with 2 Brush Heads and Travel Case
As an affiliate, we earn on qualifying purchases.
How PCA Can Be Missed
The report says the average age when PCA symptoms begin is 59, and that atypical symptoms can contribute to delays in diagnosis. Reid visited an optometrist three times, but the examinations did not identify an eye cause, according to the account. In some cases, an eye finding such as a cataract may be assumed to explain visual symptoms, potentially delaying assessment of the brain, the report says.
Keir Yong, chief investigator of a University College London longitudinal study on PCA, told Being Patient that diagnostic delays are not unusual. Yong is working with the UK Biobank on an optometrist screening test that the report says is being validated across eye and neurology clinics. The material does not provide results from that validation or say when the test might be available for routine use.
““PCA sadly can be disabling in different ways.””
— Keir Yong, speaking to Being Patient
Diagnosis and Treatment Questions Remain
The report does not say how well the screening test being developed with the UK Biobank performs, when validation will be complete or whether it will become part of routine eye care. It also does not establish how much currently available Alzheimer’s medicines help people with PCA. Eligibility for newer Alzheimer’s drugs may be difficult to determine, the report says, because cognitive tests can weigh visual and spatial abilities heavily; it cites a 2026 study finding that many people with atypical Alzheimer’s forms, including PCA, may not qualify. The study’s methods and figures are not included in the supplied material.
Individual outcomes also vary. PCA can have different underlying causes, and the report does not specify which treatments, if any, Reid is receiving. It notes that physical and occupational therapy may be relevant, but the supplied article text ends before giving further details about those services.
Screening Work and Practical Support
The next reported milestone is validation of Yong’s proposed optometrist screening test across eye and neurology clinics. Until results are available, the report’s described diagnostic approach relies on clinical assessment to rule out eye and metabolic causes, evaluate cognition and use brain imaging where appropriate. Tests of blood, cerebrospinal fluid or amyloid PET imaging may help determine whether Alzheimer’s is the underlying cause.
For people living with PCA, the report points to a need for care that addresses mobility, dressing and eating, rather than focusing only on memory. The source does not identify a specific new treatment or announce a timeline for expanded services. Decisions about evaluation or treatment should be discussed with qualified health professionals familiar with the person’s symptoms and medical history.
Key Questions
What is posterior cortical atrophy?
PCA is a syndrome that affects the brain’s ability to process visual and spatial information. It can make reading, recognizing objects, judging distances and navigating difficult, even when the eyes themselves are not the cause.
Does PCA always mean Alzheimer’s disease?
No. The Being Patient report says Alzheimer’s is the underlying cause in about 80 percent of cases; it also names dementia with Lewy bodies, prion disease and other neurodegenerative conditions as possible causes.
How is PCA assessed?
The report describes a detailed eye examination, blood tests to check for other causes, cognitive testing and brain imaging. Additional tests, including amyloid imaging or analysis of blood or cerebrospinal fluid, may help identify whether Alzheimer’s is involved.
Is there a cure or a proven PCA-specific treatment?
The report says there is no cure for PCA and that evidence for the effectiveness of medications specifically in PCA is limited. Treatment options depend in part on the underlying cause and should be discussed with a qualified clinician.
Source: rss
